Merck Licenses Zymeworks Process | Chemical & Engineering News
Volume 89 Issue 36 | p. 29 | Concentrates
Issue Date: September 5, 2011

Merck Licenses Zymeworks Process

Department: Business
News Channels: Biological SCENE

Merck & Co. will pay up to $187 million for access to bispecific antibody development technology from privately held Zymeworks. A bispecific antibody consists of two different heavy chains engineered into one molecule, enabling binding to two separate drug targets. Vancouver, British Columbia-based Zymeworks will receive an undisclosed up-front fee and research funding and could get regulatory milestones and royalties on any drugs that reach the market.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment